Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
about
The safety of daratumumab for the treatment of multiple myeloma.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
P2860
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Pharmacokinetics of Daratumuma ...... munomodulatory Drug Treatment.
@en
Pharmacokinetics of Daratumuma ...... munomodulatory Drug Treatment.
@nl
type
label
Pharmacokinetics of Daratumuma ...... munomodulatory Drug Treatment.
@en
Pharmacokinetics of Daratumuma ...... munomodulatory Drug Treatment.
@nl
prefLabel
Pharmacokinetics of Daratumuma ...... munomodulatory Drug Treatment.
@en
Pharmacokinetics of Daratumuma ...... munomodulatory Drug Treatment.
@nl
P2093
P2860
P1476
Pharmacokinetics of Daratumuma ...... munomodulatory Drug Treatment.
@en
P2093
Henk M Lokhorst
Honghui Zhou
Imran Khan
Kristen Lantz
Nedjad Losic
Pamela L Clemens
Richard Jansson
Tahamtan Ahmadi
Thomas Puchalski
Xiaoyu Yan
P2860
P2888
P304
P356
10.1007/S40262-016-0477-1
P50
P577
2016-11-29T00:00:00Z